Andrei Iancu

Andrei Iancu was under secretary of commerce for intellectual property and director of the United States Patent and Trademark Office, a position to which he was confirmed unanimously by the Senate. In this role, Mr. Iancu led an agency with approximately 13,000 employees and an annual budget of over $3.5 billion. He was also the principal adviser in the administration on domestic and international intellectual property (IP) policy matters. Mr. Iancu is now a partner at Irell & Manella, where he represents clients on IP matters. He also co-founded earlier this year the Renewing American Innovation Project at the bipartisan Center for Strategic and International Studies. Mr. Iancu has also taught patent law at the UCLA School of Law. Earlier in his career, he was an engineer at Hughes Aircraft Company.

Dr. Walter C. Copan – Congressional Testimony: The State of U.S. Science and Technology: Ensuring U.S. Global Leadership

On February 5th, 2025, Dr. Walter C. Copan testified before the House Committee on Science, Space, and Technology on the State of U.S. Science and Technology: Ensuring U.S. Global Leadership. Copan, Vice President for Research and Technology Transfer at the Colorado School of Mines, former Director of the National Institute
Read More

(Transcript) Protecting Intellectual Property for National Security: A Conversation with Rep. Nathaniel Moran (R-TX)

This transcript is from a CSIS and LeadershIP event hosted on December 3, 2024. Watch the full video here. John J. Hamre: Good afternoon, everybody. Welcome. We’re delighted to have you here. My name is John Hamre. I’m the president at CSIS. And this is going to be one
Read More

Generic Drugs, Property Rights, and the Orange Book

By Chris Borges Intellectual property (IP) rights secured through patents facilitate the introduction of dozens of new brand-name drugs and hundreds of generic drugs annually in the United States. However, proposals advanced by the Biden administration have mistakenly singled out patents as the cause of high drug prices, potentially harming the dense networks
Read More